(Q45952578)
Statements
1 reference
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. (English)
1 reference
M Bidzinski
1 reference
J M Del Campo
1 reference
A Roszak
1 reference
T E Ciuleanu
1 reference
T Hogberg
1 reference
M Z Wojtukiewicz
1 reference
A Poveda
1 reference
K Boman
1 reference
A M Westermann
1 reference
C Lebedinsky
1 reference
Yondelis Ovarian Cancer Group
1 reference
25 June 2009
1 reference
1 reference
20
1 reference
11
1 reference
1794-1802
1 reference
Identifiers
1 reference
1 reference